

Other neurological conditions

1. Bhartiya M, Kumar A, Singh RK, Radhakrishnan DM, Rajan R, Srivastava AK. Mesenchymal Stem Cell Therapy in the Treatment of Neurodegenerative Cerebellar Ataxias: a Systematic Review and Meta-analysis. *Cerebellum*. 2022 Apr 22. doi: 10.1007/s12311-022-01403-6. Epub ahead of print. PmiD: 35451803.
2. Appelt PA, Comella K, de Souza LAPS, Luvizutto GJ. Effect of stem cell treatment on functional recovery of spinocerebellar ataxia: systematic review and meta-analysis. *Cerebellum Ataxias*. 2021 Feb 25;8(1):8. doi: 10.1186/s40673-021-00130-8. PmiD: 33632326; PMCID: PMC7905903.
3. Sabino Pinho de Oliveira B, Putti S, Naro F, Pellegrini M. Bone Marrow Transplantation as Therapy for Ataxia-Telangiectasia: A Systematic Review. *Cancers*. 2020; 12(11):3207. <https://doi.org/10.3390/cancers12113207>
4. Tsai YA, Liu RS, Lirng JF, Yang BH, Chang CH, Wang YC, Wu YS, Ho JH, Lee OK, Soong BW. Treatment of spinocerebellar ataxia with mesenchymal stem cells: a phase I/IIa clinical study. Cell transplantation. 2017 Mar;26(3):503-12.<https://www.ncbi.nlm.nih.gov/pubmed/28195034>
5. Jin JL, Liu Z, Lu ZJ, Guan DN, Wang C, Chen ZB, Zhang J, Zhang WY, Wu JY, Xu Y. Safety and efficacy of umbilical cord mesenchymal stem cell therapy in hereditary spinocerebellar ataxia. *Current neurovascular research*. 2013 Feb 1;10(1):11-20. <https://www.ncbi.nlm.nih.gov/pubmed/23151076>
6. Dongmei H, Jing L, Mei X, Ling Z, Hongmin Y, Zhidong W, Li D, Zikuan G, Hengxiang W. Clinical analysis of the treatment of spinocerebellar ataxia and multiple system atrophy-cerebellar type with umbilical cord mesenchymal stromal cells. *Cytotherapy*. 2011 Sep 1;13(8):913-7. <https://www.ncbi.nlm.nih.gov/pubmed/21545234>
7. Riza Azeri, DuyguKoyuncu Irmak, Eda Sun, &ErdalKaraöz. (2021). Safety and Efficacy of The Stem Cell Transplantation in Friedreich's Ataxia: A Report of Three Cases. *International Journal of Physiotherapy*, 8(1), 31-35. <https://doi.org/10.15621/ijphy/2021/v8i1/903>
8. Shroff G. A novel approach of human embryonic stem cells therapy in treatment of Friedrich's Ataxia. *Int J Case Rep Images*. 2015 May 1;6(5):261-6.
9. Ko PW, Park S, Kang K, Lim YH, Kim SR, Suk K, Kim KS, Lee HW. Human Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Cerebellar Ataxia: A Case Report.

Medicina (Kaunas). 2021 Apr 1;57(4):334. doi: 10.3390/medicina57040334. PmiD: 33915966; PMCID: PMC8067136.

10. Petrou P, Kassis I, Ginzberg A, Hallimi M, Karussis D. Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis. *Stem Cells Transl Med*. 2022 Mar 3;11(1):55-58. doi: 10.1093/stcltm/szab017. PmiD: 35641166; PMCID: PMC8895488.
11. Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, Fagius J, Rose J, Nelson F, Barreira AA, Carlson K, Han X, Moraes D, Morgan A, Quigley K, Yaung K, Buckley R, Alldredge C, Clendenan A, Calvario MA, Henry J, Jovanovic B, Helenowski IB. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. *JAMA*. 2019 Jan 15;321(2):165-174. doi: 10.1001/jama.2018.18743. PmiD: 30644983; PMCID: PMC6439765.
12. Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. MEsenchymalStEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. *Trials*. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z. PmiD: 31072380; PMCID: PMC6507027.
13. Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, Fagius J, Rose J, Nelson F, Barreira AA, Carlson K, Han X, Moraes D, Morgan A, Quigley K, Yaung K, Buckley R, Alldredge C, Clendenan A, Calvario MA, Henry J, Jovanovic B, Helenowski IB. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. *JAMA*. 2019 Jan 15;321(2):165-174. doi: 10.1001/jama.2018.18743. PmiD: 30644983; PMCID: PMC6439765.
14. Mancardi GL, Sormani MP, Gualandi F, Saiz A, Carreras E, Merelli E, Donelli A, Lugaresi A, Di Bartolomeo P, Rottoli MR, Rambaldi A. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. *Neurology*. 2015 Mar 10;84(10):981-8.
15. Sharrack B, Snowden J, Muraro P. 019 Autologous stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis (StarMS).

16. Nabizadeh F, Pirahesh K, Rafiei N, Afrashteh F, Ahmadabad MA, Zabeti A, mirmosayyeb O. Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis. *Neurol Ther*. 2022 Jul 28;1–17. doi: 10.1007/s40120-022-00389-x. Epub ahead of print. PmiD: 35902484; PMCID: PMC9333355.
17. Alghwiri AA, Jamali F, Aldughmi M, Khalil H, Al-Sharman A, Alhattab D, Al-Radaideh A, Awidi A. The effect of stem cell therapy and comprehensive physical therapy in motor and non-motor symptoms in patients with multiple sclerosis: A comparative study. *Medicine (Baltimore)*. 2020 Aug 21;99(34):e21646. doi: 10.1097/MD.00000000000021646. PmiD: 32846775; PMCID: PMC7447403.
18. Sormani MP, Muraro PA, Schiavetti I, Signori A, Laroni A, Saccardi R, Mancardi GL. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis. *Neurology*. 2017 May 30;88(22):2115-22.
19. Reston JT, Uhl S, Treadwell JR, Nash RA, Schoelles K. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. *Multiple Sclerosis Journal*. 2011 Feb;17(2):204-13.
20. Zhou Y, Zhang X, Xue H, Liu L, Zhu J, Jin T. Autologous mesenchymal stem cell transplantation in multiple sclerosis: a meta-analysis. *Stem cells international*. 2019 Dec 23;2019.
21. Ge F, Lin H, Li Z, Chang T. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis. *Neurological Sciences*. 2019 Mar;40(3):479-87.
22. Zhang, P., Liu, B. Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis. *Bone Marrow Transplant* 55, 1928–1934 (2020).
23. Cui J, Jin L, Ding M, He J, Yang L, Cui S, Wang X, Ma J, Liu A. Efficacy and safety of mesenchymal stem cells in the treatment of systemic sclerosis: a systematic review and meta-analysis. *Stem Cell Res Ther*. 2022 Mar 21;13(1):118. doi: 10.1186/s13287-022-02786-3. PmiD: 35313985; PMCID: PMC8935249.
24. Patti F, Chisari CG, Toscano S, Arena S, Finocchiaro C, Cimino V, milone G. Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature. *Journal of Clinical Medicine*. 2022 Feb 11;11(4):942.

25. Casanova, B., Jarque, I., Gascón, F. et al. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. *Neurol Sci* 38, 1213–1221 (2017).
26. Bose G, Atkins HL, Bowman M, Freedman MS. Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis. *MultScler*. 2019 Nov;25(13):1764-1772. doi: 10.1177/1352458518802544. Epub 2018 Sep 25. PmiD: 30251913.
27. Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E, Carreras E, Graus F, Kashyap A, Openshaw H, Schipperus M, Deconinck E, Mancardi G, Marmont A, Hansz J, Rabusin M, Zuazu Nagore FJ, Besalduch J, Dentamaro T, Fouillard L, Hertenstein B, La Nasa G, Musso M, Papineschi F, Rowe JM, Saccardi R, Steck A, Kappos L, Gratwohl A, Tyndall A, Samijn J; Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation). Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. *J Neurol*. 2002 Aug;249(8):1088-97. doi: 10.1007/s00415-002-0800-7. Erratum in: *J Neurol*. 2002 Nov;249(11):1619..Samign, J [corrected to Samijn, J]. Erratum in: *J Neurol*. 2002 Oct;249(10):1482. PmiD: 12195460.
28. Saccardi R, Kozak T, Bocelli-Tyndall C, et al. Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. *Multiple Sclerosis Journal*. 2006;12(6):814-823. doi:10.1177/1352458506071301
29. Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. *Haematologica*. 2010 Feb;95(2):284-292. DOI: 10.3324/haematol.2009.013458.
30. Ni XS, Ouyang J, Zhu WH, Wang C, Chen B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. *Clinical Transplantation*. 2006 Jul-Aug;20(4):485-489. DOI: 10.1111/j.1399-0012.2006.00510.x.
31. Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R; Multiple Sclerosis–Autologous Hematopoietic

Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. *JAMA Neurol.* 2017 Apr 1;74(4):459-469. doi: 10.1001/jamaneurol.2016.5867. PmiD: 28241268; PMCID: PMC5744858.

32. Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. *Multiple Sclerosis Journal.* 2018 Apr;24(4):501-11.
33. Chen B, Zhou M, Ouyang J, Zhou R, Xu J, Zhang Q, Yang Y, Xu Y, Shao X, Meng L, Wang J. Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China. *Neurological Sciences.* 2012 Aug;33(4):881-6.
34. Carreras E, Saiz A, Marín P, Martínez C, Rovira M, Villamor N, Aymerich M, Lozano M, Fernández-Avilés F, Urbano-Ispizua A, Montserrat E. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. *haematologica.* 2003 Jan 1;88(3):306-14.
35. Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, Tsompanakou A. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. *Bone marrow transplantation.* 1997 Oct;20(8):631-8.
36. Kvistad SA, Lehmann AK, Trovik LH, Kristoffersen EK, Bø L, Myhr KM, Torkildsen Ø. Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. *Multiple Sclerosis Journal.* 2020 Dec;26(14):1889-97.
37. Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, Vrethem M, Fredrikson S, Martin C, Sandstedt A, Uggla B. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. *Journal of Neurology, Neurosurgery & Psychiatry.* 2014 Oct 1;85(10):1116-21.
38. Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, Smias C, Eleftheriadis N, Tsimourtou V. Autologous stem cell transplantation in progressive multiple sclerosis—an interim analysis of efficacy. *Journal of clinical immunol*
39. Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D. Immunoablation and autologous haemopoietic stem-cell

transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. *The Lancet*. 2016 Aug 6;388(10044):576-85.

40. Mancardi GL, Sormani MP, Di Gioia M, Vuolo L, Gualandi F, Amato MP, Capello E, Currò D, Uccelli A, Bertolotto A, Gasperini C. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. *Multiple Sclerosis Journal*. 2012 Jun;18(6):835-42.
41. Petrou P, Kassis I, Levin N, Paul F, Backner Y, Benoliel T, Oertel FC, Scheel M, Hallimi M, Yaghmour N, Hur TB, Ginzberg A, Levy Y, Abramsky O, Karussis D. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. *Brain*. 2020 Dec 1;143(12):3574-3588. doi: 10.1093/brain/awaa333. PmiD: 33253391.
42. Tremblay F, Ansari Y, Remaud A, Freedman MS. Neurophysiological outcomes following mesenchymal stem cell therapy in multiple sclerosis. *Clin Neurophysiol*. 2022 Apr;136:69-81. doi: 10.1016/j.clinph.2022.01.125. Epub 2022 Jan 29. PmiD: 35149266.
43. Harris VK, Stark JW, Yang S, Zanker S, Tuddenham J, Sadiq SA. Mesenchymal stem cell-derived neural progenitors in progressive MS: Two-year follow-up of a phase I study. *Neurol NeuroimmunolNeuroinflamm*. 2020 Dec 4;8(1):e928. doi: 10.1212/NXI.0000000000000928. PmiD: 33277427; PMCID: PMC7738177.
44. Berard JA, Freedman MS, Marrie RA, Marriott JJ, Atkins HL, Szwajcer D, Courtman DW, Thebault S, Walker LAS. Mesenchymal stem cell therapy and cognition in MS: Preliminary findings from a phase II clinical trial. *MultSclerRelatDisord*. 2022 May;61:103779. doi: 10.1016/j.msard.2022.103779. Epub 2022 Mar 27. PmiD: 35367874.
45. Shroff G. Transplantation of human embryonic stem cells in patients with multiple sclerosis and lyme disease. *The American Journal of Case Reports*. 2016;17:944.
46. Sahraian MA, MohyeddinBonab M, Baghbanian SM, Owji M, Naser Moghadasi A. Therapeutic use of intrathecal mesenchymal stem cells in patients with multiple sclerosis: a pilot study with booster injection. *Immunological Investigations*. 2019 Feb 17;48(2):160-8.
47. Currò D, Mancardi G. Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience. *Neurological Sciences*. 2016 Jun;37(6):857-65.
48. Shroff G. Human embryonic stem cell for the treatment of multiple sclerosis: a case report. *Case Reports International*. 2015 Dec 1(4):38-42.

49. Hou ZL, Liu Y, Mao XH, Wei CY, Meng MY, Liu YH, Zhuyun Yang Z, Zhu H, Short M, Bernard C, Xiao ZC. Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis. *Cell adhesion & migration*. 2013 Sep 25;7(5):404-7.
50. Polgar S, Buultjens M, Wijeratne T, Finkelstein DI, Mohamed S, Karimi L. The Placebo Response in Double-Blind Randomised Trials Evaluating Regenerative Therapies for Parkinson's Disease: A Systematic Review and Meta-Analysis. *J Parkinsons Dis*. 2022;12(3):759-771. doi: 10.3233/JPD-212610. PmiD: 35034910.
51. Wang J, Tian Y, Shi X, Feng Z, Jiang L, Hao Y. Safety and Efficacy of Cell Transplantation on Improving Motor Symptoms in Patients With Parkinson's Disease: A Meta-Analysis. *Front Hum Neurosci*. 2022 May 6;16:849069. doi: 10.3389/fnhum.2022.849069. PmiD: 35601911; PMCID: PMC9120834.
52. Carstens M, Haq I, Martinez-Cerrato J, Dos-Anjos S, Bertram K, Correa D. Sustained clinical improvement of Parkinson's disease in two patients with facially-transplanted adipose-derived stromal vascular fraction cells. *J Clin Neurosci*. 2020 Nov;81:47-51. doi: 10.1016/j.jocn.2020.09.001. Epub 2020 Sep 25. PmiD: 33222965.
53. Venkataramana N. K., Kumar S. K., Balaraju S., Radhakrishnan R. C., Bansal A., Dixit A., et al. (2010). Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. *Transl. Res*. 155 62–70. 10.1016/j.trsl.2009.07.006
54. Lige, L., & Zengmin, T. (2016). Transplantation of Neural Precursor Cells in the Treatment of Parkinson Disease: An Efficacy and Safety Analysis. *Turkish neurosurgery*, 26(3), 378–383. <https://doi.org/10.5137/1019-5149.JTN.10747-14.4>
55. Madrazo I., Kopyov O., Ávila-Rodríguez M. A., Ostrosky F., Carrasco H., Kopyov A., et al. (2019). Transplantation of human neural progenitor cells (NPC) into putamina of Parkinsonian patients: a case series study, safety and efficacy four years after surgery. *Cell Transplant*. 28 269–285. 10.1177/0963689718820271
56. Bachoud-Lévi AC; on behalf the Multicentric Intracerebral Grafting in Huntington's Disease Group. Human Fetal Cell Therapy in Huntington's Disease: A Randomized, Multicenter, Phase II Trial. *Mov Disord*. 2020 Aug;35(8):1323-1335. doi: 10.1002/mds.28201. Epub 2020 Jul 15. PmiD: 32666599.

57. Mohseni R, Hamidieh AA, Shoaee-Hassani A, Ghahvechi-Akbari M, Majma A, Mohammadi M, Nikougoftar M, Shervin-Badv R, Ai J, Montazerlotfelahi H, Ashrafi MR. An open-label phase 1 clinical trial of the allogeneic side population adipose-derived mesenchymal stem cells in SMA type 1 patients. *Neurol Sci.* 2022 Jan;43(1):399-410. doi: 10.1007/s10072-021-05291-2. Epub 2021 May 25. PMID: 34032944.
58. Li H, Yuan F, Du Y, Pan T, Wen W, Li S, Wang L, Lu A. Umbilical cord blood stem cells transplantation in a patient with severe progressive supranuclear palsy: a case report. *Journal of Medical Case Reports* [Internet]. 2021 Nov 29 [cited 2022 Sep 22];15(1). Available from: <https://doi.org/10.1186/s13256-021-03139-z>